查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2071536

肝細胞癌：全球市場展望、流行病學、競爭格局和市場預測報告（32個主要市場），2025-2035年

Global Hepatocellular Carcinoma - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 156 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 英國uHCC 市場預計將從 2025 年的 4,900 萬美元成長到 2035 年的 7,100 萬美元，顯示市場穩步擴張。
  • 以下因素正在推動市場成長：
  • 擴大高成本聯合治療。
  • 透過改進診斷技術擴大合格的患者範圍
  • 儘管流行病學成長是漸進的，但高價生物製藥和較長的治療週期支撐了市場規模。
  • 歐洲完善的保險報銷機制持續促進人們獲得創新療法。
  • 未來的成長將取決於下一代免疫療法和針對抗藥性機制的新型聯合治療策略。

肝細胞癌（HCC）概述

肝細胞癌（HCC）是最常見的原發性肝臟惡性腫瘤，主要發生於慢性肝病或肝硬化患者。C型肝炎病毒感染、酒精性肝病、代謝功能障礙相關的脂肪肝以及黃麴毒素暴露是導致致癌性變的主要原因。除TERT啟動子、TP53、CTNNB1和ARID1A的體細胞突變外，表觀遺傳失調也是腫瘤發生的基礎。患者通常表現為右上腹疼痛、體重減輕、黃疸和補償肝病，許多病例是在監測項目中偶然發現的。根據EASL和AASLD的標準，除了血清甲胎蛋白造影外，如果在多期造影CT或MRI檢查中證實動脈期強化和靜脈期造影消失，即使在肝硬化患者中，也可以無需切片檢查即可確診。巴塞隆納臨床肝癌分期系統綜合考慮腫瘤負荷、肝功能和體能狀態，指南治療方案的選擇。對於早期病變，手術切除或消融是根治性治療；對於符合米蘭標準的病例，肝臟移植是根治性治療。對於中期疾病，可採用經動脈化療栓塞術和放射性栓塞術。免疫療法的加入顯著改變了全身性治療方案。Atezolizumab合併貝Bevacizumab、Durvalumab利尤單抗合併曲美木單抗是進行性肝細胞癌的第一線治療方案，Lenvatinib和Sorafenib作為替代治療方案。Cabozantinib、Ramucirumab和Regorafenib則作為二線治療方案。預後因疾病分期和肝功能準備而異。多學科管理、最佳化後續觀察和以患者為中心的輔助治療對於長期療效至關重要。

主要亮點

  • 在法國，預計新增病例數將從 2025 年的 7,874 例增加到 2035 年的 8,033 例，這表明疾病負擔略有增加。
  • 診斷率仍高達 85.0%，反映出整個醫療保健系統具有很高的偵測能力。
  • 治療率仍只有 76.2%，凸顯了確診患者與接受治療的患者之間仍然存在的差距。
  • 治療模式已轉變為以免疫療法為基礎的聯合治療（IO + 抗 VEGF/CTLA-4），這已成為新的治療標準。
  • 儘管近年來治療方面取得了進展，但晚期疾病和難治性疾病患者的治療需求仍未得到滿足。

市場定義：

  • 北美洲（美國、加拿大）
  • 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
  • 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
  • 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
  • 非洲（埃及、奈及利亞、南非、摩洛哥）
  • 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

格式化和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於微軟Excel）
  • 流行病學數據（MS Excel，互動式工具）
  • 高階主管洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 如何最佳化在 32 個市場（北美、歐洲、中東、亞太、非洲和南美/拉丁美洲）的藥物開發和生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興的治療方法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

  • 北美洲（美國、加拿大）
  • 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
  • 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
  • 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
  • 非洲（埃及、奈及利亞、南非、摩洛哥）
  • 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

大公司

  • InnoBM Pharmaceuticals Co., Ltd.
  • Chengdu New Radiomedicine Technology Co. LTD.
  • BeiGene
  • Hoffmann-La Roche
  • Beijing Gene Key Life Technology Co., Ltd
  • Akeso
  • AstraZeneca
  • Tvardi Therapeutics, Incorporated
  • Genentech, Inc.
  • RayzeBio, Inc.
  • Shanghai Henlius Biotech

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業利益與風險等。

第2章：疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

  • 重點
  • 發病率/盛行率
  • 已確診並正在接受藥物治療的患者族群。
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 按藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 目前主要療法－概述及關鍵意見領袖見解
  • 新興療法
  • 重點
  • 值得關注的後期新興療法—概述、市場上市預期和關鍵意見領袖見解
  • 值得關注的早期研發管線

第6章：未滿足的需求與TPP分析

  • 尚未滿足的主要需求及其透過新興療法實現的潛力。
  • TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

簡介目錄

Global Hepatocellular Carcinoma Market Outlook

Thelansis's "Global Hepatocellular Carcinoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hepatocellular Carcinoma treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Hepatocellular Carcinoma (HCC) Overview

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, arising predominantly in the context of chronic liver disease and cirrhosis, with hepatitis B and C viral infections, alcohol-related liver disease, metabolic dysfunction-associated steatotic liver disease, and aflatoxin exposure representing principal aetiological drivers of oncogenic hepatocyte transformation. Somatic alterations in TERT promoter, TP53, CTNNB1, and ARID1A alongside epigenetic dysregulation underpin tumourigenesis. Patients present with right upper quadrant pain, weight loss, jaundice, and decompensated liver disease, with many diagnosed incidentally through surveillance programmes. Serum alpha-fetoprotein alongside multiphasic contrast-enhanced CT or MRI demonstrating arterial enhancement with venous washout establishes diagnosis without biopsy in cirrhotic patients, per EASL and AASLD criteria. Barcelona Clinic Liver Cancer staging integrates tumour burden, liver function, and performance status to guide therapeutic allocation. Surgical resection or ablation offers curative intent in early-stage disease, with liver transplantation providing definitive treatment within Milan criteria. Transarterial chemoembolisation and radioembolisation address intermediate-stage disease. Systemic therapy has been transformed by immunotherapy combinations; atezolizumab plus bevacizumab and durvalumab plus tremelimumab are established first-line standards for advanced HCC, with lenvatinib and sorafenib as alternatives. Cabozantinib, ramucirumab, and regorafenib address second-line disease. Prognosis varies markedly with stage and hepatic reserve; multidisciplinary management, surveillance optimisation, and patient-centred supportive care are integral to long-term outcomes.

Key Highlights

  • In France, incident cases are projected to increase from 7,874 in 2025 to 8,033 by 2035, indicating marginal growth in disease burden.
  • Diagnosis rate remains high at 85.0%, reflecting strong detection capabilities across healthcare systems.
  • Treatment rate stands at 76.2%, highlighting a residual gap between diagnosed and treated patients.
  • The treatment paradigm has shifted toward immunotherapy-based combinations (IO + anti-VEGF/CTLA-4) as the new standard of care.
  • Persistent unmet need exists in post-progression settings and treatment-resistant populations, despite recent therapeutic advances.

Market Overview

  • The United Kingdom uHCC market is projected to grow from $49M in 2025 to $71M by 2035, reflecting steady market expansion.
  • Market growth is driven by:
  • Increasing adoption of high-cost immunotherapy combinations
  • Expansion of eligible patient population due to improved diagnosis
  • Despite modest epidemiological growth, market value is supported by premium-priced biologics and longer treatment duration.
  • Strong reimbursement frameworks in Europe continue to facilitate access to innovative therapies.
  • Future growth will depend on next-generation immunotherapies and novel combination strategies targeting resistance mechanisms.

Market Definition:

  • North America (United States, Canada)
  • Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
  • Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
  • Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
  • Africa (Egypt, Nigeria, South Africa, Morocco)
  • South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • North America (United States, Canada)
  • Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
  • Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
  • Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
  • Africa (Egypt, Nigeria, South Africa, Morocco)
  • South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

  • InnoBM Pharmaceuticals Co., Ltd.
  • Chengdu New Radiomedicine Technology Co. LTD.
  • BeiGene
  • Hoffmann-La Roche
  • Beijing Gene Key Life Technology Co., Ltd
  • Akeso
  • AstraZeneca
  • Tvardi Therapeutics, Incorporated
  • Genentech, Inc.
  • RayzeBio, Inc.
  • Shanghai Henlius Biotech

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)